The United Laboratories International Holdings Limited (ULIHF) Comparison with companies in other sectors?

The United Laboratories International Holdings Limited has a share price of 1.82B. You can analyze The United Laboratories International Holdings Limited (ULIHF) competitors across different market sectors through stock heatmaps.

What are ULIHF's NET and operating margins?

The United Laboratories International Holdings Limited (ULIHF) operating margin is around 0.25, and net profit margin is approximately 0.21 as of the latest reports.

In what way does ULIHF's earnings per share (EPS) trend reflect its financial momentum?

The United Laboratories International Holdings Limited (ULIHF) EPS is 0.20 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for The United Laboratories International Holdings Limited is 9.25, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for The United Laboratories International Holdings Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for The United Laboratories International Holdings Limited like P/E which is 8.28, P/B which is 1.67, and PEG which is 0.01. Compare them with sector averages to evaluate if the stock is priced fairly.

The United Laboratories International Holdings Limited

ULIHF•PNK

Healthcare

Drug Manufacturers - Specialty & Generic

$1.85

$0.00(0.00%)

Fundamental Analysis of The United Laboratories International Holdings Limited (ULIHF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.20

P/E Ratio

9.25

ROE

0.21%

Net Margin

0.21%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$3.36B

Shares OutstandingTotal number of shares issued

$1.82B

Book Value/ShareNet worth per share

$7.94

Revenue/ShareAnnual revenue per share

$7.71

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.2

Net MarginNet income as percentage of revenue

20.76%

Operating MarginOperating income as percentage of revenue

24.85%

ROEReturn on shareholders' equity

20.84%

ROAReturn on total assets

11.26%

ROCEReturn on capital employed

20.40%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.83

Cash/ShareCash and equivalents per share

$3.48

FCF YieldFree cash flow as percentage of market cap

6.24%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$0.20

Dividend YieldAnnual dividend as percentage of stock price

1.52%

Financial Ratios Analysis data is not available for ULIHFFinancial Ratios Analysis details for ULIHF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for ULIHFSector Benchmarking details for ULIHF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for The United Laboratories International Holdings Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of The United Laboratories International Holdings Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account The United Laboratories International Holdings Limited's unique business strengths and challenges.

Key Financial Metrics for The United Laboratories International Holdings Limited

For The United Laboratories International Holdings Limited, essential financial indicators include EPS 0.20, PE 9.25, and ROE 0.21. These key ratios reveal insights into The United Laboratories International Holdings Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare The United Laboratories International Holdings Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of The United Laboratories International Holdings Limited

Metrics like Net Margin 20.76% and ROA 11.26% shed light on how well The United Laboratories International Holdings Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether The United Laboratories International Holdings Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of The United Laboratories International Holdings Limited

Using ratios such as P/B Ratio 1.67 and PEG Ratio 0.01, investors can assess whether The United Laboratories International Holdings Limited is appropriately valued based on its financials and growth potential. These figures, combined with The United Laboratories International Holdings Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for The United Laboratories International Holdings Limited

Financial health indicators, such as Debt/Equity Ratio 0.22 and Cash Flow $0.83, provide a snapshot of The United Laboratories International Holdings Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like The United Laboratories International Holdings Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for The United Laboratories International Holdings Limited

Investing in The United Laboratories International Holdings Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at The United Laboratories International Holdings Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;